During 2012, an observational study confirmed the high risk of cardiovascular disease ascribed to chronic kidney disease (CKD) and again raised the question of whether CKD should be considered a cardiovascular disease risk equivalent. Several other studies evaluated methods to mitigate cardiovascular risk in CKD. The results of these studies have advanced the field but have also raised more questions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154–2169 (2003).
Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 380, 807–814 (2012).
Lambers Heerspink, H. J. et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 82, 330–337 (2012).
Vegter, S. et al. Sodium intake, ACE inhibition, and progression to ESRD. J. Am. Soc. Nephrol. 23, 165–173 (2012).
O'Donnell, M. J. et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 306, 2229–2238 (2012).
Olesen, J. B. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 367, 625–635 (2012).
Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 20, 2223–2233 (2009).
Thadhani, R. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 307, 674–684 (2012).
The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. http://dx.doi.org/10.1056/NEJMoa1205624.
US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States [online], (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Garimella, P., Sarnak, M. Moving forward, slowly but surely. Nat Rev Nephrol 9, 69–70 (2013). https://doi.org/10.1038/nrneph.2012.285
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.285
